What Орнисид treats: Main Uses and Benefits

Ornidazole is an agent applied across therapeutic domains for addressing infections caused by susceptible protozoa and anaerobic bacteria.

The agent is considered relevant for the management of conditions such as amoebiasis (infections of the liver and intestines), giardiasis, and trichomoniasis, which are conditions involving episodic or fluctuating manifestations. It is also commonly used to help with nonspecific vaginitis.

The medication is further utilized in clinical settings for managing anaerobic bacterial infections, and is often applied in scenarios requiring surgical antibiotic prophylaxis where short-term symptomatic assistance is needed to help with post-operative symptom management. This provides support that may assist with easing the overall symptom burden.

“Ornidazole is commonly used to help manage symptoms related to physical discomfort and systemic imbalance associated with these types of infections.”

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning

The medication helps address symptom clusters that may become intense or disruptive in these conditions presenting with systemic or localized discomfort, and supports general well-being during symptomatic phases.

Regulatory References

1. Ethiopian Food and Drug Administration (EFDA) document

Who Can and Cannot Use Орнисид?

Eligibility for Орнисид (Ornidazole) is strictly defined by regulatory documents based on patient population, physiological status, and pre-existing medical conditions.

---

Absolute Contraindications

Ornidazole must not be used in patients who have a known hypersensitivity to the medicine, or to any other nitroimidazole derivative (e.g., Metronidazole).

It is also contraindicated during the first trimester of pregnancy and in patients with established organic Central Nervous System (CNS) diseases, such as epilepsy or disseminated sclerosis (multiple sclerosis).

---

Condition-Based and Physiological Restrictions

Population Group	Regulatory Status	Restriction Type
Adults and Children	Use is permitted	Age-group eligibility; pediatric use is weight-based.
Severe Hepatic Impairment	Conditional use	Dosing interval must be doubled.
Renal Impairment	Conditional use	Supplemental dose required after haemodialysis.
Lactation	Not recommended	Use requires weighing benefit vs. risk; not routinely prescribed.

---

Special Precaution is required for patients with a history of blood disorders, often requiring monitoring of leukocyte counts before and after therapy.

Interactions with other medicines and products

Official regulatory information documents specific interactions between Ornidazole (Орнисид) and several other medicines, products, and medical conditions, primarily concerning changes in drug clearance and potentiating effects.

---

Official Regulatory Interaction Status

Classification	Interacting Substance	Official Constraint or Result
High Restriction	Alcohol (Ethanol)	Must be avoided during treatment and for at least 3 days after therapy ends.
High Restriction	Disulfiram	Co-administration is strongly discouraged due to the risk of acute confusion or psychosis.
Clearance Altered	Cimetidine	May decrease Ornidazole plasma clearance and prolong its half-life.
Clearance Altered	Phenobarbital/Phenytoin	May reduce the half-life of Ornidazole.
Effect Potentiation	Coumarin Anticoagulants	May intensify the anticoagulant effect, requiring monitoring.
Effect Potentiation	Vecuronium Bromide	May prolong the muscle relaxant effect.
Co-Drug Clearance	5-Fluorouracil	Ornidazole may reduce its clearance, leading to increased plasma levels.

---

Population-Specific Interaction Note

Regulatory labels specify that patients with marked hepatic impairment require an adjustment to the administration schedule: the dosage interval should be doubled. This is due to altered drug clearance in this specific population, which otherwise could lead to accumulation of Ornidazole. No other population-specific restrictions are universally documented in the context of interactions.

How Орнисид Works

The mechanism of action of Ornidazole is based on a targeted sequence of chemical reduction and subsequent cytotoxicity. Ornidazole functions as a prodrug that requires activation by specific microbial enzymes. Its action is initiated by interacting with the unique low-redox potential electron transport components, such as Ferredoxin, found exclusively in susceptible anaerobic bacteria and protozoa.

This enzymatic interaction causes the drug's NO2 group to accept electrons, transforming the inert molecule into highly reactive free radical intermediates. These intermediates are cytotoxic and immediately attack the microbe's most critical structure: its DNA. These reactive species chemically disrupt the DNA helix, causing strand breakage and inhibiting the synthesis and repair of genetic material. The resultant damage to the DNA structure leads directly to microbial cell death (a bactericidal and antiprotozoal effect), which is the core physiological consequence of the mechanism.

The functional scope of the mechanism is constrained by oxygen antagonism, as high O2 concentrations compete for the necessary electrons, limiting activation and biological activity.

Ornidazole is an antibiotic and antiprotozoal agent used to treat susceptible anaerobic bacterial and protozoal infections, including amoebiasis, giardiasis, and trichomoniasis. It is available in various forms, including oral tablets and intravenous solutions. All administration should follow the specific directions provided by your healthcare provider, based on your age, body weight, the type of infection, and its severity.

Oral Tablet Administration

• Timing: Ornidazole tablets must always be taken with or after food to help minimize potential gastrointestinal discomfort, such as an upset stomach or nausea.
• Consistency: Take the medication at approximately the same time(s) each day to maintain consistent drug levels in the bloodstream.
• Course Completion: To effectively eradicate the infection and prevent resistance, it is critical to complete the full prescribed course of treatment, even if symptoms begin to improve.

General Dosing Guidelines (Adults)

• Trichomoniasis & Giardiasis: Treatment often involves either a single large dose or a course of 500 mg tablets taken once or twice daily for several days. For trichomoniasis, it is generally recommended that the sexual partner be treated simultaneously to avoid reinfection.
• Amoebic Dysentery: Treatment may involve a once-daily dose for three days. For other forms of amoebiasis, a more prolonged course of up to ten days may be necessary.

Indication (Adults)	Typical Regimen	Duration (Example)
Trichomoniasis	Single dose (e.g., 1.5 g) OR 500 mg twice daily	1 day or 5 days
Amoebic Dysentery	1.5 g once daily	3 days
Giardiasis	1.5 g once daily	1–2 days

Note: Dosage for children is calculated based on body weight (mg/kg) and is typically given in a single daily dose or two divided doses.

Important Considerations

• Missed Dose: If an oral dose is forgotten, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not take a double dose to compensate.
• Vomiting: If you vomit within 30 minutes of taking an oral dose, take the same dose again. If vomiting occurs more than 30 minutes later, simply wait for the next scheduled dose.

Research evidence / Overview of Studies for Орнисид

---

Evidence for Protozoal Infections (Amoebiasis, Giardiasis, and Trichomoniasis)

Research exploring Ornidazole for protozoal infections was evaluated in short-term randomized trials and their subsequent systematic reviews. These studies were conducted during periods of increased symptom activity and were evaluated in order to measure whether the organism causing the infection could be cleared (parasitological cure) and how the associated outcomes related to physical discomfort (such as diarrhea and abdominal pain) were measured during the study period. The research examined both adult populations and pediatric patients (children) with confirmed infections.

The short-term findings describe patterns observed in the studies where researchers reported measurements of parasitic clearance and symptom resolution in the observed populations. The pattern of measured outcomes for this drug class was observed in some studies; this research contributes to the broader evidence landscape.

Evidence for Anaerobic Bacterial Infections

Studies exploring Ornidazole’s use for infections caused by anaerobic bacteria, including conditions like nonspecific vaginitis, involve comparative clinical trials and research exploring short-term symptom changes. These trials monitored patients with infections across different areas of the body. Research examined outcomes related to systemic or functional imbalance, specifically focusing on measured rates of clinical cure and successful bacteriological eradication.

Findings from the research describe patterns observed in the studies where researchers reported measured changes related to symptom evolution and the clearance of the targeted bacteria. Studies report how symptoms evolved in the observed populations over the defined time intervals of the trial. However, findings were mixed when comparing outcomes across different infection sites, suggesting that results may depend on the location and specific type of anaerobic infection being studied.

Evidence for Surgical Site Infection Prophylaxis

Research examined the use of Ornidazole in studies based on Multicentre Randomized, Double-Blind, Placebo-Controlled Trials. These studies were evaluated in adults undergoing specific high-risk elective surgical procedures, such as colorectal surgery. The trials research examined a specific outcome: the incidence of Surgical Site Infection (SSI) within 30 days following the procedure.

The trials findings describe patterns observed in the studies regarding the rate of SSI when Ornidazole was included as part of the prophylactic regimen, compared to control groups. This research contributes to the broader evidence landscape by monitoring conditions characterized by fluctuating or episodic manifestations in the post-operative period.

Research Gaps and Uncertainty

Follow-up durations were limited in many studies, meaning that there is limited information for long-term outcomes such as the sustained durability of parasitic or bacterial clearance. For instance, evidence related to the use of Ornidazole in older adults or patients with significant pre-existing health conditions (comorbidities) is limited, and data for certain groups remain insufficient.

Key Studies & References

1. Efficacy and safety of different drugs for the treatment of bacterial vaginosis: a systematic review and network meta-analysis - Frontiers
2. Ornidazole-Induced Liver Injury: The Clinical Characterization of a Rare Adverse Reaction and Its Implications from a Multicenter Study
3. CONSUMER MEDICINE INFORMATION ARROW – ORNIDAZOLE (Regulatory/Patient Information Document)

Common questions about Орнисид (FAQ)

Q: How long does it usually take for Орнисид to start working?

The time it takes for the effects of this medicine to become noticeable can vary. Official product information indicates that the onset of action is dependent on the specific form of the medicine used and the way it is administered (for instance, whether it is taken as an oral tablet or given as an intravenous infusion).

Q: Can older adults use Орнисид safely?

The medicine's label information applies to the general adult population, which includes older adults. However, official sources note that research studies specifically focused on outcomes and data for older adults may be limited. General adult guidelines apply where specific restrictions are not noted.

Q: Can women who are breastfeeding use Орнисид?

Use of the medicine during lactation is generally not recommended in official documents. Official reports indicate that avoidance of breastfeeding for a specified period after a single dose may allow drug levels in the mother's milk to decrease significantly.

Q: Does taking Орнисид require any special lab tests?

Official information states that monitoring, such as leukocyte counts (a type of blood test), may be required for patients with a history of blood disorders. The use of the medicine in patients with severe hepatic (liver) or renal (kidney) impairment also requires specific monitoring or dose adjustment based on official requirements.

Q: What evidence themes about Орнисид are commonly discussed in medical literature?

Research themes described in official overviews include studies examining the drug’s use for protozoal infections, anaerobic bacterial infections, and for surgical site infection prophylaxis (prevention). Official documents also note important research gaps, such as limited data on long-term outcomes and durability of effects.

Q: Is Орнисид the same as Ornidazole?

Орнисид is the trade or brand name used for the medicine. It contains the single active ingredient, which is known as Ornidazole.

Q: Are there any long-term side effects associated with Орнисид?

Official information notes that clinical research studies of the drug have generally had limited follow-up durations. This means that comprehensive long-term outcome data, including information on sustained effects and safety over many months or years, are not extensively documented in the product literature.

Q: Can Орнисид cause changes in sleep patterns?

Official documents list potential adverse reactions associated with the use of this medicine. Changes in sleep patterns, specifically sleeplessness (insomnia), have been noted as a potential side effect in official reports.

Q: Is it normal to have mild headaches after starting Орнисид?

Official documents classify headache as a common adverse reaction associated with the drug. A 'common' classification indicates that this effect is one of the more frequently observed outcomes reported with the medicine.

Q: What age groups is Орнисид suitable for?

The medicine is generally indicated for use in both adults and children. Official dosing guidelines confirm that the medicine can be used in children, with the exact dosage determined based on the child's body weight (mg/kg).

Q: What is the typical timeframe for stopping the use of Орнисид before drinking alcohol?

Official regulatory constraints state that alcohol (ethanol) must be strictly avoided during treatment with the medicine. Furthermore, regulatory constraints indicate that alcohol avoidance should continue for a specified period, such as at least 3 days, after the full therapy course has been completed.

Q: Can the drug be crushed or split, or must it be taken whole?

Official product information describes the intended method of administration as swallowing the tablets whole with a glass of water.

Q: How does Ornidazole's longer half-life compare to Metronidazole?

While direct comparisons are avoided in regulatory documents, official pharmacokinetic data for Ornidazole provides its elimination half-life. This data indicates that the drug's half-life is approximately 13 hours.

Q: Is it possible for Орнисид to cause nerve problems?

Yes, this is noted in official safety information. Documents list potential nerve problems (such as Peripheral Neuropathy) and other central nervous system disorders as rare, serious adverse reactions. Official documents specify that discontinuation of treatment may be warranted if signs of these effects develop.

Q: What is the recommended duration of treatment for Орнисид?

The duration of treatment is short-term and is entirely dependent on the specific infection being addressed. Treatment courses generally range from as short as one day up to ten days, as detailed in the official prescribing information for specific uses.

Q: Are there any mental or mood changes noted as side effects of Орнисид?

Official safety warnings note that the medicine is contraindicated in patients with established organic Central Nervous System (CNS) diseases. In some individuals, the drug may cause CNS disorders, including confusion and ataxia (loss of coordination).

Q: Does weight affect how Орнисид works?

Yes, regulatory dosing guidelines indicate that body weight is a factor in calculating the appropriate amount of the medicine. Specifically, for children, the dosage is calculated and administered based on body weight (mg/kg).

Q: Can Орнисид make you feel tired or dizzy?

Official documentation lists both dizziness and unusual tiredness and weakness as potential adverse reactions associated with the use of the medicine.

Q: Is there a pediatric formulation of Орнисид available?

Official documents list the available forms as tablets, vaginal tablets, and solution for infusion. Pediatric dosing is provided using the existing oral forms (e.g., tablets dosed by weight) and the infusion solution, rather than a separate liquid or syrup formulation.

Q: Are there common foods or drinks that shouldn't be consumed while taking Орнисид?

The only substance specifically listed in official regulatory constraints that must be strictly avoided is alcohol (ethanol), due to the risk of interaction. The tablets, however, are generally advised to be taken with or after food.

Storage and Protection Requirements

Ornidazole must be stored according to regulatory guidelines to maintain potency. All formulations should be stored at temperatures not exceeding 25 C. The product must be kept in the original package and protected from light. For the solution for infusion, it is specifically required that the product not be frozen.

Child Safety and Handling

It is a mandatory requirement that Ornidazole, in all its forms, must be stored out of the sight and reach of children.

Disposal Instructions

Upon expiry or when no longer needed, the medicine must be disposed of properly. Ornidazole must not be thrown away in household waste or wastewater. Instead, any unused or expired product must be returned to a pharmacist or an approved collection point. Any remaining portion of the single-dose infusion solution must be discarded immediately after use.